Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients

Detalhes bibliográficos
Autor(a) principal: Cardoso,Leila C.A.
Data de Publicação: 2012
Outros Autores: Castaño,Jair A. Tenorio, Pereira,Hanna S., Lima,Maria Angélica de F.D., Santos,Anna Cláudia E. dos, Faria,Paulo S. de, Ferman,Sima, Seuánez,Héctor N., Nevado,Julián B., Almeida,José Carlos Cabral de, Lapunzina,Pablo, Vargas,Fernando R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Genetics and Molecular Biology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572012000500002
Resumo: The most frequent epigenetic alterations in Wilms tumor (WT) occur at WT2, assigned to 11p15. WT2 consists of two domains: telomeric domain 1 (DMRH19) that contains the IGF2 gene and an imprinted maternally expressed transcript (H19) and centromeric domain 2 (KvDMR) that contains the genes KCNQ1, KCNQ1OT1 and CDKN1C. In this work, we used pyrosequencing and MS-MLPA to compare the methylation patterns of DMRH19/KvDMR in blood and tumor samples from 40 WT patients. Normal constitutional KvDMR methylation indicated that most of the epigenetic alterations in WT occur at DMRH19. Constitutional DMRH19 hypermethylation (HM DMRH19) was observed in two patients with Beckwith-Wiedemann syndrome. Pyrosequencing and MS-MLPA showed HM DMRH19 in 28/34 tumor samples: 16/34 with isolated HM DMRH19 and 12/34 with concomitant HM DMRH19 and KvDMR hypomethylation, indicating paternal uniparental disomy. With the exception of one blood sample, the MS-MLPA and pyrosequencing findings were concordant. Diffuse or focal anaplasia was present in five tumor samples and was associated with isolated somatic HM DMRH19 in four of them. Constitutional 11p15 methylation abnormalities were present in 5% of the samples and somatic abnormalities in the majority of tumors. Combined analysis of DMRH19/KvDMR by pyrosequencing and MS-MLPA is beneficial for characterizing epigenetic anomalies in WT, and MS-MLPA is useful and reliable for estimation of DNA methylation in a clinical setting.
id SBG-1_0875838494ccbbbcc914e81da59ba272
oai_identifier_str oai:scielo:S1415-47572012000500002
network_acronym_str SBG-1
network_name_str Genetics and Molecular Biology
repository_id_str
spelling Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patientsepigenetichistopathologymethylationMS-MLPApyrosequencingThe most frequent epigenetic alterations in Wilms tumor (WT) occur at WT2, assigned to 11p15. WT2 consists of two domains: telomeric domain 1 (DMRH19) that contains the IGF2 gene and an imprinted maternally expressed transcript (H19) and centromeric domain 2 (KvDMR) that contains the genes KCNQ1, KCNQ1OT1 and CDKN1C. In this work, we used pyrosequencing and MS-MLPA to compare the methylation patterns of DMRH19/KvDMR in blood and tumor samples from 40 WT patients. Normal constitutional KvDMR methylation indicated that most of the epigenetic alterations in WT occur at DMRH19. Constitutional DMRH19 hypermethylation (HM DMRH19) was observed in two patients with Beckwith-Wiedemann syndrome. Pyrosequencing and MS-MLPA showed HM DMRH19 in 28/34 tumor samples: 16/34 with isolated HM DMRH19 and 12/34 with concomitant HM DMRH19 and KvDMR hypomethylation, indicating paternal uniparental disomy. With the exception of one blood sample, the MS-MLPA and pyrosequencing findings were concordant. Diffuse or focal anaplasia was present in five tumor samples and was associated with isolated somatic HM DMRH19 in four of them. Constitutional 11p15 methylation abnormalities were present in 5% of the samples and somatic abnormalities in the majority of tumors. Combined analysis of DMRH19/KvDMR by pyrosequencing and MS-MLPA is beneficial for characterizing epigenetic anomalies in WT, and MS-MLPA is useful and reliable for estimation of DNA methylation in a clinical setting.Sociedade Brasileira de Genética2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572012000500002Genetics and Molecular Biology v.35 n.4 2012reponame:Genetics and Molecular Biologyinstname:Sociedade Brasileira de Genética (SBG)instacron:SBG10.1590/S1415-47572012005000073info:eu-repo/semantics/openAccessCardoso,Leila C.A.Castaño,Jair A. TenorioPereira,Hanna S.Lima,Maria Angélica de F.D.Santos,Anna Cláudia E. dosFaria,Paulo S. deFerman,SimaSeuánez,Héctor N.Nevado,Julián B.Almeida,José Carlos Cabral deLapunzina,PabloVargas,Fernando R.eng2012-12-10T00:00:00Zoai:scielo:S1415-47572012000500002Revistahttp://www.gmb.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||editor@gmb.org.br1678-46851415-4757opendoar:2012-12-10T00:00Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG)false
dc.title.none.fl_str_mv Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
title Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
spellingShingle Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
Cardoso,Leila C.A.
epigenetic
histopathology
methylation
MS-MLPA
pyrosequencing
title_short Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
title_full Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
title_fullStr Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
title_full_unstemmed Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
title_sort Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients
author Cardoso,Leila C.A.
author_facet Cardoso,Leila C.A.
Castaño,Jair A. Tenorio
Pereira,Hanna S.
Lima,Maria Angélica de F.D.
Santos,Anna Cláudia E. dos
Faria,Paulo S. de
Ferman,Sima
Seuánez,Héctor N.
Nevado,Julián B.
Almeida,José Carlos Cabral de
Lapunzina,Pablo
Vargas,Fernando R.
author_role author
author2 Castaño,Jair A. Tenorio
Pereira,Hanna S.
Lima,Maria Angélica de F.D.
Santos,Anna Cláudia E. dos
Faria,Paulo S. de
Ferman,Sima
Seuánez,Héctor N.
Nevado,Julián B.
Almeida,José Carlos Cabral de
Lapunzina,Pablo
Vargas,Fernando R.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cardoso,Leila C.A.
Castaño,Jair A. Tenorio
Pereira,Hanna S.
Lima,Maria Angélica de F.D.
Santos,Anna Cláudia E. dos
Faria,Paulo S. de
Ferman,Sima
Seuánez,Héctor N.
Nevado,Julián B.
Almeida,José Carlos Cabral de
Lapunzina,Pablo
Vargas,Fernando R.
dc.subject.por.fl_str_mv epigenetic
histopathology
methylation
MS-MLPA
pyrosequencing
topic epigenetic
histopathology
methylation
MS-MLPA
pyrosequencing
description The most frequent epigenetic alterations in Wilms tumor (WT) occur at WT2, assigned to 11p15. WT2 consists of two domains: telomeric domain 1 (DMRH19) that contains the IGF2 gene and an imprinted maternally expressed transcript (H19) and centromeric domain 2 (KvDMR) that contains the genes KCNQ1, KCNQ1OT1 and CDKN1C. In this work, we used pyrosequencing and MS-MLPA to compare the methylation patterns of DMRH19/KvDMR in blood and tumor samples from 40 WT patients. Normal constitutional KvDMR methylation indicated that most of the epigenetic alterations in WT occur at DMRH19. Constitutional DMRH19 hypermethylation (HM DMRH19) was observed in two patients with Beckwith-Wiedemann syndrome. Pyrosequencing and MS-MLPA showed HM DMRH19 in 28/34 tumor samples: 16/34 with isolated HM DMRH19 and 12/34 with concomitant HM DMRH19 and KvDMR hypomethylation, indicating paternal uniparental disomy. With the exception of one blood sample, the MS-MLPA and pyrosequencing findings were concordant. Diffuse or focal anaplasia was present in five tumor samples and was associated with isolated somatic HM DMRH19 in four of them. Constitutional 11p15 methylation abnormalities were present in 5% of the samples and somatic abnormalities in the majority of tumors. Combined analysis of DMRH19/KvDMR by pyrosequencing and MS-MLPA is beneficial for characterizing epigenetic anomalies in WT, and MS-MLPA is useful and reliable for estimation of DNA methylation in a clinical setting.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572012000500002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572012000500002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1415-47572012005000073
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Genética
publisher.none.fl_str_mv Sociedade Brasileira de Genética
dc.source.none.fl_str_mv Genetics and Molecular Biology v.35 n.4 2012
reponame:Genetics and Molecular Biology
instname:Sociedade Brasileira de Genética (SBG)
instacron:SBG
instname_str Sociedade Brasileira de Genética (SBG)
instacron_str SBG
institution SBG
reponame_str Genetics and Molecular Biology
collection Genetics and Molecular Biology
repository.name.fl_str_mv Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG)
repository.mail.fl_str_mv ||editor@gmb.org.br
_version_ 1752122385348165632